On June 16, 2020 the Company entered into an amendment to the Revolving Credit Facility to temporarily increase the maximum leverage ratio to 4.25 to 1.00 after the March 31, 2020 reporting period through the December 31, 2020 reporting period with a maximum leverage ratio of 3.75 to 1.00 thereafter.We have chosen to voluntarily comply with the amended rules effective during the three months ended March 31, 2020.As it relates to the income approach for the Europe reporting unit at March 31, 2020 and April 1, 2020, the Company forecasted cash flows for the next 5 years.For the nine months ended September 30, 2020, the Company incurred expenses amounting to approximately $192.3 million for incremental manufacturing variances, site remediation and restructuring charges related to the Morgantown plant, as well as continued product rationalization.Financial SummaryThe tables below are a summary of the Company’ s financial results for the three and nine months ended September 30, 2020 compared to the prior year periods: A detailed discussion of the Company’ s financial results can be found below in the section titled“ Results of Operations.”The graph below shows net sales by segment for the three months ended September 30, 2020 and 2019 and the net change period over period: North America SegmentNet sales from North America decreased by $59.8 million or 5% during the three months ended September 30, 2020 when compared to the prior year period.A reconciliation between cost of sales, as reported under U. S. GAAP, and adjusted cost of sales and adjusted gross margin for the three months ended September 30, 2020 compared to the three months ended September 30, 2019 is as follows: (a) Adjusted gross profit is calculated as total revenues less adjusted cost of sales.The following table includes the losses/(gains) recognized in litigation settlements and other contingencies, net during the three months ended September 30, 2020 and September 30, 2019: During the three months ended September 30, 2020, the Company recorded a $16.9 million loss for fair value adjustments related to Pfizer’ s proprietary dry powder inhaler delivery platform (the“ respiratory delivery platform”) contingent consideration and a net charge of approximately $2.0 million related to a number of litigation matters.The decrease is primarily due to lower average long-term debt balances during the current quarter as compared to the prior year period.A reconciliation between cost of sales, as reported under U. S. GAAP, and adjusted cost of sales and adjusted gross margin for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019 is as follows: (a) Adjusted gross profit is calculated as total revenues less adjusted cost of sales.The following table includes the losses/(gains) recognized in litigation settlements and other contingencies, net during the nine months ended September 30, 2020 and September 30, 2019: During the nine months ended September 30, 2020, the Company recorded a $35.6 million loss for fair value adjustments related to respiratory delivery platform contingent consideration.Other expense, net was comprised of the following for the nine months ended September 30, 2020 and 2019, respectively: Included in other gains for the nine months ended September 30, 2020 was a $16.5 million gain for a fair value adjustment relate to a non-marketable investment which the Company holds.During the nine months ended September 30, 2020, the Company recognized a net charge as a result of adjustments to reserves for uncertain tax positions, partially offset by changes in the assessment of the realizability of deferred tax assets.During the nine months ended September 30, 2019, the Company reached a settlement in principle with the IRS to resolve federal tax matters related to the 66 Table of ContentsFebruary 27, 2015 acquisition by Mylan N. V. of Mylan Inc. and Abbott Laboratories’ non-U. S. developed markets specialty and branded generics business, including adjusting the interest rates used for intercompany loans and confirming our status as a non-U. S. corporation for U. S. federal income tax purposes, and recorded a reserve of approximately $140.0 million as part of its liability for uncertain tax positions, with a net impact to the income tax provision of approximately $129.9 million related to this matter.During the nine months ended September 30, 2019, primarily due to the settlement in principle reached with the IRS and the expiration of federal and foreign statutes of limitations, the Company increased its net liability for unrecognized tax benefits by approximately $46.1 million.The three months ended September 30, 2019 includes costs related to incremental manufacturing variances and site remediation activities as a result of the activities at the Company’ s Morgantown plant of approximately $50.0 million.The nine months ended September 30, 2019 includes charges for certain incremental manufacturing variances and site 69 Table of Contentsremediation activities as a result of the activities at the Company’ s Morgantown plant, product recall costs, including inventory write-offs, and charges related to the cancellation of a contract.R & D expense for the three months ended September 30, 2019 consists primarily of payments for product development.Reconciliation of U. S. GAAP Net Earnings to EBITDA and Adjusted EBITDABelow is a reconciliation of U. S. GAAP net earnings (loss) to EBITDA and adjusted EBITDA for the three and nine months ended September 30, 2020 compared to the prior year period: (a) Includes clean energy investment financing and accretion of contingent consideration.The Company is in compliance at September 30, 2020 and expects to remain in compliance for the next twelve months.The following table presents unaudited summarized financial information of Mylan N. V. and Mylan Inc. on a combined basis as of and for the nine months ended September 30, 2020 and as of and for the year ended December 31, 2019.